179 related articles for article (PubMed ID: 33999322)
1. The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia.
Cox IA; de Graaff B; Ahmed H; Campbell J; Otahal P; Corte TJ; Glaspole I; Moodley Y; Goh N; Macansh S; Walters EH; Palmer AJ
Qual Life Res; 2021 Sep; 30(9):2615-2632. PubMed ID: 33999322
[TBL] [Abstract][Full Text] [Related]
2. Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AQoL-8D.
Cox IA; Campbell J; de Graaff B; Otahal P; Corte TJ; Moodley Y; Hopkins P; Macansh S; Walters EH; Palmer AJ
Qual Life Res; 2023 Feb; 32(2):473-493. PubMed ID: 35927542
[TBL] [Abstract][Full Text] [Related]
3. The impact of multiple sclerosis severity on health state utility values: Evidence from Australia.
Ahmad H; Taylor BV; van der Mei I; Colman S; O'Leary BA; Breslin M; Palmer AJ
Mult Scler; 2017 Jul; 23(8):1157-1166. PubMed ID: 27698247
[TBL] [Abstract][Full Text] [Related]
4. A systematic literature review of health state utility values in head and neck cancer.
Meregaglia M; Cairns J
Health Qual Life Outcomes; 2017 Sep; 15(1):174. PubMed ID: 28865475
[TBL] [Abstract][Full Text] [Related]
5. The impact of age on health utility values for older women with early-stage breast cancer: a systematic review and meta-regression.
Wang Y; Gavan SP; Steinke D; Cheung KL; Chen LC
Health Qual Life Outcomes; 2022 Dec; 20(1):169. PubMed ID: 36564800
[TBL] [Abstract][Full Text] [Related]
6. Measuring the health-related quality of life in Australians with multiple sclerosis using the assessment of quality of life-8-dimension (AQoL-8D) multi-attribute utility instrument.
Ahmad H; van der Mei I; Taylor BV; Campbell JA; Palmer AJ
Mult Scler Relat Disord; 2020 Sep; 44():102358. PubMed ID: 32650122
[TBL] [Abstract][Full Text] [Related]
7. The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument.
Zheng Q; Cox IA; de Graaff B; Campbell JA; Corte TJ; Glaspole I; Navaratnam V; Hopkins P; Zappala C; Ahmad H; Zhao T; Macansh S; Walters EH; Palmer AJ
Qual Life Res; 2023 Jun; 32(6):1609-1619. PubMed ID: 36572788
[TBL] [Abstract][Full Text] [Related]
8. Health Utilities for Multiple Sclerosis.
Hawton A; Green C
Value Health; 2016 Jun; 19(4):460-8. PubMed ID: 27325338
[TBL] [Abstract][Full Text] [Related]
9. The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study.
Cox IA; de Graaff B; Ahmed H; Campbell J; Otahal P; Corte TJ; Moodley Y; Goh N; Hopkins P; Macansh S; Walters EH; Palmer AJ
Eur J Health Econ; 2023 Sep; 24(7):1121-1139. PubMed ID: 36289130
[TBL] [Abstract][Full Text] [Related]
10. Health state utility values (QALY weights) for Huntington's disease: an analysis of data from the European Huntington's Disease Network (EHDN).
Hawton A; Green C; Goodwin E; Harrower T
Eur J Health Econ; 2019 Dec; 20(9):1335-1347. PubMed ID: 31410669
[TBL] [Abstract][Full Text] [Related]
11. Exploring health state utility values of parents of children with a serious illness.
Majmudar IK; Engel L; Muscara F; Stevenson C; McCarthy M; Anderson V; Mihalopoulos C
Qual Life Res; 2020 Jul; 29(7):1947-1959. PubMed ID: 32335816
[TBL] [Abstract][Full Text] [Related]
12. Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review.
Brockbank J; Krause T; Moss E; Pedersen AM; Mørup MF; Ahdesmäki O; Vaughan J; Brodtkorb TH
Health Qual Life Outcomes; 2021 Mar; 19(1):94. PubMed ID: 33736649
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
Jo HE; Glaspole I; Grainge C; Goh N; Hopkins PM; Moodley Y; Reynolds PN; Chapman S; Walters EH; Zappala C; Allan H; Keir GJ; Hayen A; Cooper WA; Mahar AM; Ellis S; Macansh S; Corte TJ
Eur Respir J; 2017 Feb; 49(2):. PubMed ID: 28232409
[TBL] [Abstract][Full Text] [Related]
14. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.
Jo HE; Glaspole I; Moodley Y; Chapman S; Ellis S; Goh N; Hopkins P; Keir G; Mahar A; Cooper W; Reynolds P; Haydn Walters E; Zappala C; Grainge C; Allan H; Macansh S; Corte TJ
BMC Pulm Med; 2018 Jan; 18(1):19. PubMed ID: 29370786
[TBL] [Abstract][Full Text] [Related]
15. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry.
Kreuter M; Swigris J; Pittrow D; Geier S; Klotsche J; Prasse A; Wirtz H; Koschel D; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Kahn N; Welte T; Neurohr C; Schwaiblmair M; Held M; Bahmer T; Oqueka T; Frankenberger M; Behr J
Respir Res; 2019 Mar; 20(1):59. PubMed ID: 30876420
[TBL] [Abstract][Full Text] [Related]
16. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry.
O'Brien EC; Hellkamp AS; Neely ML; Swaminathan A; Bender S; Snyder LD; Culver DA; Conoscenti CS; Todd JL; Palmer SM; Leonard TB;
Chest; 2020 May; 157(5):1188-1198. PubMed ID: 31954102
[TBL] [Abstract][Full Text] [Related]
17. EQ-5D-Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review.
Golicki D; Jaśkowiak K; Wójcik A; Młyńczak K; Dobrowolska I; Gawrońska A; Basak G; Snarski E; Hołownia-Voloskova M; Jakubczyk M; Niewada M
Value Health; 2020 Jul; 23(7):953-968. PubMed ID: 32762998
[TBL] [Abstract][Full Text] [Related]
18. Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis.
Buchanan-Hughes AM; Buti M; Hanman K; Langford B; Wright M; Eddowes LA
Qual Life Res; 2019 Feb; 28(2):297-319. PubMed ID: 30225787
[TBL] [Abstract][Full Text] [Related]
19. Health State Utility Values of Type 2 Diabetes Mellitus and Related Complications: A Systematic Review and Meta-Analysis.
Redenz G; Ibaceta MC; Aceituno D; Balmaceda C; Espinoza MA
Value Health Reg Issues; 2023 Mar; 34():14-22. PubMed ID: 36371899
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
